6780 related articles for article (PubMed ID: 3144768)
1. New type of plasminogen activator produced by an established cell line from human ovary.
Matsuo O; Fukao H; Matsuo C; Ueshima S
Thromb Res Suppl; 1988; 8():45-55. PubMed ID: 3144768
[TBL] [Abstract][Full Text] [Related]
2. Characterization of plasminogen activator produced by an established cell line from human ovary.
Matsuo C; Fukao H; Matsuo O
J Cell Physiol; 1988 Feb; 134(2):253-60. PubMed ID: 3126195
[TBL] [Abstract][Full Text] [Related]
3. Purification and properties of a single-chain urokinase-type plasminogen activator form produced by subcultured human umbilical vein endothelial cells.
Booyse FM; Lin PH; Traylor M; Bruce R
J Biol Chem; 1988 Oct; 263(29):15139-45. PubMed ID: 3170576
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
[TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of a plasma factor which cleaves single-chain form of t-PA and u-PA.
Okada K; Fukao H; Tanaka H; Ueshima S; Matsuo O
Thromb Res Suppl; 1990; 10():27-43. PubMed ID: 2156352
[TBL] [Abstract][Full Text] [Related]
6. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
8. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
[TBL] [Abstract][Full Text] [Related]
9. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.
Rijken DC; Collen D
J Biol Chem; 1981 Jul; 256(13):7035-41. PubMed ID: 6787058
[TBL] [Abstract][Full Text] [Related]
10. Production and characterization of single-chain tissue-type plasminogen activator produced by an established cell line from human uterine muscle.
Matsuo O; Fukao H; Izaki S; Matsuo C; Ueshima S
Cell Struct Funct; 1989 Feb; 14(1):45-60. PubMed ID: 2497995
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
Bykowska K; Rijken DC; Collen D
Thromb Haemost; 1981 Oct; 46(3):642-4. PubMed ID: 7198301
[TBL] [Abstract][Full Text] [Related]
12. Characterization of plasminogen activator from two human renal carcinoma cell lines.
Nelson NF; Cieplak W; Dacus SC; Prager MD
J Cell Physiol; 1986 Mar; 126(3):435-43. PubMed ID: 2419348
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54,000) from cultured human endothelial cells indistinguishable from urinary urokinase.
Booyse FM; Osikowicz G; Feder S; Scheinbuks J
J Biol Chem; 1984 Jun; 259(11):7198-205. PubMed ID: 6539333
[TBL] [Abstract][Full Text] [Related]
14. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Andreasen PA; Christensen TH; Huang JY; Nielsen LS; Wilson EL; Danø K
Mol Cell Endocrinol; 1986 May; 45(2-3):137-47. PubMed ID: 3011558
[TBL] [Abstract][Full Text] [Related]
15. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
[TBL] [Abstract][Full Text] [Related]
16. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
Lijnen HR; Piérard L; Reff ME; Gheysen D
Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
[TBL] [Abstract][Full Text] [Related]
18. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA).
Fischer BE
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415
[TBL] [Abstract][Full Text] [Related]
20. Partial purification and characterization of epidermal plasminogen activator and their inhibitor.
Nakagawa M; Fukuyama K; Epstein WL; Hara A; Sawada H
Chem Pharm Bull (Tokyo); 1989 Jul; 37(7):1859-63. PubMed ID: 2509088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
